Dabiri Yaghoub, Mahadevan Vaikom S, Guccione Julius M, Kassab Ghassan S
California Medical Innovations Institute, San Diego, CA, United States.
University of California San Francisco, San Diego, CA, United States.
Front Genet. 2023 Mar 9;14:1142446. doi: 10.3389/fgene.2023.1142446. eCollection 2023.
Severe mitral regurgitation (MR) is a mitral valve disease that can lead to lifethreatening complications. MitraClip (MC) therapy is a percutaneous solution for patients who cannot tolerate surgical solutions. In MC therapy, a clip is implanted in the heart to reduce MR. To achieve optimal MC therapy, the cardiologist needs to foresee the outcomes of different scenarios for MC implantation, including the location of the MC. Although finite element (FE) modeling can simulate the outcomes of different MC scenarios, it is not suitable for clinical usage because it requires several hours to complete. In this paper, we used machine learning (ML) to predict the outcomes of MC therapy in less than 1 s. Two ML algorithms were used: XGBoost, which is a decision tree model, and a feed-forward deep learning (DL) model. The MC location, the geometrical attributes of the models and baseline stress and MR were the features of the ML models, and the predictions were performed for MR and maximum von Mises stress in the leaflets. The parameters of the ML models were determined to achieve the minimum errors obtained by applying the ML models on the validation set. The results for the test set (not used during training) showed relative agreement between ML predictions and ground truth FE predictions. The accuracy of the XGBoost models were better than DL models. Mean absolute percentage error (MAPE) for the XGBoost predictions were 0.115 and 0.231, and the MAPE for DL predictions were 0.154 and 0.310, for MR and stress, respectively. The ML models reduced the FE runtime from 6 hours (on average) to less than 1 s. The accuracy of ML models can be increased by increasing the dataset size. The results of this study have important implications for improving the outcomes of MC therapy by providing information about the outcomes of MC implantation in real-time.
重度二尖瓣反流(MR)是一种可导致危及生命并发症的二尖瓣疾病。MitraClip(MC)疗法是针对无法耐受手术治疗的患者的一种经皮治疗方案。在MC疗法中,将一个夹子植入心脏以减少二尖瓣反流。为了实现最佳的MC疗法,心脏病专家需要预见MC植入不同方案的结果,包括MC的位置。尽管有限元(FE)建模可以模拟不同MC方案的结果,但由于其需要数小时才能完成,因此不适合临床使用。在本文中,我们使用机器学习(ML)在不到1秒的时间内预测MC疗法的结果。使用了两种ML算法:作为决策树模型的XGBoost和前馈深度学习(DL)模型。MC的位置、模型的几何属性以及基线应力和二尖瓣反流是ML模型的特征,并针对小叶中的二尖瓣反流和最大冯·米塞斯应力进行预测。确定ML模型的参数以实现通过将ML模型应用于验证集而获得的最小误差。测试集(训练期间未使用)的结果表明ML预测与地面真值FE预测之间具有相对一致性。XGBoost模型的准确性优于DL模型。XGBoost预测的平均绝对百分比误差(MAPE)对于二尖瓣反流和应力分别为0.115和0.231,而DL预测的MAPE分别为0.154和0.310。ML模型将FE运行时间从平均6小时减少到不到1秒。通过增加数据集大小可以提高ML模型的准确性。本研究结果对于通过实时提供MC植入结果的信息来改善MC疗法的结果具有重要意义。